Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - insulin isophane human; insulin soluble human - suspension for injection - 70unit/1ml ; 30unit/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - insulin soluble human; insulin isophane human - suspension for injection - 30unit/1ml ; 70unit/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - insulin isophane human; insulin soluble human - suspension for injection - 70unit/1ml ; 30unit/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - insulin soluble human; insulin isophane human - suspension for injection - 30unit/1ml ; 70unit/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

pilsco ltd - insulin soluble human; insulin isophane human - suspension for injection - 30unit/1ml ; 70unit/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - insulin isophane human; insulin soluble human - suspension for injection - 70unit/1ml ; 30unit/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - insulin soluble human; insulin isophane human - suspension for injection - 30unit/1ml ; 70unit/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

pharmaram ltd - insulin isophane human; insulin soluble human - suspension for injection - 70unit/1ml ; 30unit/1ml

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

eli lilly and company - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. humulin n is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] , and - in patients who have had hypersensitivity reactions to humulin n or any of its excipients [see warnings and precautions (5.5)] . risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7% and has been reported to be as high as 20-25% in women with a hba1c >10%. the estimated background risk of miscarriage for the indicated population is unkn

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - insulin isophane human - suspension for injection - 100unit/1ml